STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more

<iframe
  src="https://statesidedaily.com/embed/cluster/8118d241a9fdcf0df2b4c6a10defbf4744e60e00"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about payments to Russian middlemen, a possible Dupixent rival, and more"></iframe>